AUTHORS
Wenhua Wang, Jiayi Han2, Xinjie Bi3, Xia Liu4, Xianhuo Wang, PhD5, Huilai Zhang, PhD6
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
6 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
ABSTRACT
Among TP53 hotspot mutations, the R175 residue mutation exhibits the highest frequency. This mutation impairs zinc ion binding, leading to severe misfolding and loss of function of the p53 protein, making it a well-recognized subtype in p53-targeted therapeutic research. Typical subtypes of aggressive B-cell lymphoma include mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). Indole-dione compounds have been reported to possess anticancer properties. Ferroptosis, a form of regulated cell death, has recently emerged as a potential cancer therapeutic strategy. However, the role of ferroptosis in mediating the effects of indole-dione drugs on aggressive B-cell lymphoma remains unclear. This study aims to screen a small-molecule compound library to identify agents capable of selectively eliminating TP53R175H-mutant aggressive B-cell lymphoma cell lines, and to further investigate them in vivo efficacy, safety profile, and the underlying mechanisms of action.
By collecting data from our institution, collaborating institutions, and public databases, we analyzed TP53 mutation characteristics and the association between hotspot mutations and prognosis. Through screening a small-molecule compound library, we identified compound 211H as a small-molecule agent that selectively kills TP53R175H-mutant cells. We investigated the mode of cell death induced by 211H through in vitro and in vivo experiments. By analyzing transcriptomic data and performing virtual docking, we determined the target of 211H and further validated it through in vitro experiments.
In this study, we found that TP53R175 mutation is significantly associated with poor overall survival in patients. In vitro, compound 211H selectively induced apoptosis and G2 phase cell cycle arrest in TP53R175H-mutant aggressive B-cell lymphoma cells. In vivo, it exhibited potent antitumor activity with a favorable safety profile. Further mechanistic investigation revealed that the cytotoxic effect of 211H on TP53R175H-mutant cells not only depends on the induction of apoptosis but also involves the activation of ferroptosis. The ferroptosis-suppressive effect was specifically observed in TP53R175H-mutant cells. Mechanistically, 211H directly binds to the deubiquitinase USP8, thereby inhibiting its interaction with SLC7A11, a key regulator of the ferroptosis pathway. This disruption promotes K48-linked polyubiquitination and subsequent degradation of SLC7A11, ultimately activating the ferroptosis pathway and leading to cell death.
In summary, we identified a critical anti-tumor function of the indolinone compound 211H in selectively eliminating aBCL cells. Our data reveal that 211H exerts potent cytotoxicity against TP53R175H mutant aBCL via the synergistic induction of apoptosis and ferroptosis. Mechanistically, 211H binds to the deubiquitinase USP8 and disrupts the interaction between USP8 and the master ferroptosis regulator SLC7A11. This dissociation facilitates K48-linked polyubiquitination of SLC7A11, elevates its overall ubiquitination level, and ultimately accelerates proteasomal degradation of SLC7A11. Loss of SLC7A11 subsequently activates the ferroptosis cascade to elicit robust anti-tumor effects. Collectively, these findings establish a novel mechanistic framework to support precision therapeutic strategies for patients harboring TP53R175H mutant malignancies.
DISCLOSURES
Wenhua Wang: No relevant conflicts of interest to declare.